EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Hepatic manifestations of hereditary haemorrhagic telangiectasia

Claire Kelly iD, Elisabetta Buscarini, Guido Manfredi, Stephen Gregory, Michael A Heneghan

Liver International · 2024

DOI: 10.1111/liv.16008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver International, 2024. Verfasst von Claire Kelly und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Liver Studies, Kings College Hospital, London, UK. Hauptthemen laut MEDLINE: Telangiectasia, Hereditary Hemorrhagic, Liver Transplantation. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 91 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hereditary haemorrhagic telangiectasia is a genetic condition of abnormal blood vessel formation resulting from an imbalance of pro‐ and anti‐angiogenic products of the transforming growth factor β/bone morphogenetic protein signalling pathway which contributes to vascular remodelling and maintenance. Hepatic vascular malformations are common although less frequently symptomatic, but may result in high‐output cardiac failure, portal hypertension and biliary ischaemia. Whilst the understanding of the genetic and cell signalling pathways that are the hallmark of hereditary haemorrhagic telangiectasia have been clarified, there remain challenges in therapy for these patients. Only patients with symptomatic hepatic vascular malformations require treatment, with most (63%) responding to first‐line medical therapy. For non‐responders, bevacizumab is effective in reducing cardiac output in those with heart failure secondary to hepatic vascular malformations as well as other manifestations of the disease. Although liver transplantation is the only curative option, optimal timing is critical. Novel anti‐angiogenetic drugs and those that target aberrant cell signalling pathway are being explored.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Telangiectasia, Hereditary HemorrhagicLiver TransplantationHumansAngiogenesis InhibitorsLiverSignal TransductionHypertension, PortalBevacizumab

Stichwörter der Autor:innen

VEGFangiogenesishereditary haemorrhagic telangiectasialiver transplantationvascular malformation

Substanzen

Angiogenesis InhibitorsBevacizumab

Autor:innen und Institutionen

  • Institute of Liver Studies, Kings College Hospital, London, UK.
  • VASCERN HHT Reference Centre, ASST Maggiore Hospital, Crema, Italy.
  • Department of Radiology, Kings College Hospital, London, UK.

ORCID-Profile: Claire Kelly

Zitieren

APA

Kelly, C., Buscarini, E., Manfredi, G., Gregory, S., & Heneghan, M. A. (2024). Hepatic manifestations of hereditary haemorrhagic telangiectasia. Liver International. https://doi.org/10.1111/liv.16008

Vancouver

Kelly C, Buscarini E, Manfredi G, Gregory S, Heneghan MA. Hepatic manifestations of hereditary haemorrhagic telangiectasia. Liver International. 2024. doi:10.1111/liv.16008

BibTeX
@article{Kelly2024,
  author = {Kelly, Claire and Buscarini, Elisabetta and Manfredi, Guido and Gregory, Stephen and Heneghan, Michael A},
  title = {Hepatic manifestations of hereditary haemorrhagic telangiectasia},
  journal = {Liver International},
  year = {2024},
  doi = {10.1111/liv.16008}
}
Kostenlos starten →